Compile Data Set for Download or QSAR
maximum 50k data
Found 363 of ph data with Target = 'TGF-beta receptor type-1'
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM35939(4-pyridinoxy-2-anilinopyridine-based compound, 1)
Affinity DataIC50:  44nM EC50:  55nMpH: 7.4 T: 2°CAssay Description:A fluorescence polarization assay was used to assess the ALK5 binding capacity and biochemical activity of compounds. ALK5 protein was added to each ...More data for this Ligand-Target Pair
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM35941(4-pyridinoxy-2-anilinopyridine-based compound, 5)
Affinity DataIC50:  13nM EC50:  20nMpH: 7.4 T: 2°CAssay Description:A fluorescence polarization assay was used to assess the ALK5 binding capacity and biochemical activity of compounds. ALK5 protein was added to each ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM35942(4-pyridinoxy-2-anilinopyridine-based compound, 6)
Affinity DataIC50:  35nM EC50:  21nMpH: 7.4 T: 2°CAssay Description:A fluorescence polarization assay was used to assess the ALK5 binding capacity and biochemical activity of compounds. ALK5 protein was added to each ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM35943(4-pyridinoxy-2-anilinopyridine-based compound, 7)
Affinity DataIC50:  227nM EC50: >5.80E+3nMpH: 7.4 T: 2°CAssay Description:A fluorescence polarization assay was used to assess the ALK5 binding capacity and biochemical activity of compounds. ALK5 protein was added to each ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM35944(4-pyridinoxy-2-anilinopyridine-based compound, 8)
Affinity DataIC50:  108nM EC50:  282nMpH: 7.4 T: 2°CAssay Description:A fluorescence polarization assay was used to assess the ALK5 binding capacity and biochemical activity of compounds. ALK5 protein was added to each ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM35945(4-pyridinoxy-2-anilinopyridine-based compound, 9)
Affinity DataIC50:  107nM EC50:  628nMpH: 7.4 T: 2°CAssay Description:A fluorescence polarization assay was used to assess the ALK5 binding capacity and biochemical activity of compounds. ALK5 protein was added to each ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM35946(4-pyridinoxy-2-anilinopyridine-based compound, 10)
Affinity DataIC50:  7nM EC50:  114nMpH: 7.4 T: 2°CAssay Description:A fluorescence polarization assay was used to assess the ALK5 binding capacity and biochemical activity of compounds. ALK5 protein was added to each ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM35947(4-pyridinoxy-2-anilinopyridine-based compound, 11)
Affinity DataIC50:  739nM EC50: >3.00E+3nMpH: 7.4 T: 2°CAssay Description:A fluorescence polarization assay was used to assess the ALK5 binding capacity and biochemical activity of compounds. ALK5 protein was added to each ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM35948(4-pyridinoxy-2-anilinopyridine-based compound, 12)
Affinity DataIC50:  4nM EC50:  32nMpH: 7.4 T: 2°CAssay Description:A fluorescence polarization assay was used to assess the ALK5 binding capacity and biochemical activity of compounds. ALK5 protein was added to each ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM35949(4-pyridinoxy-2-anilinopyridine-based compound, 13)
Affinity DataIC50:  6nM EC50:  62nMpH: 7.4 T: 2°CAssay Description:A fluorescence polarization assay was used to assess the ALK5 binding capacity and biochemical activity of compounds. ALK5 protein was added to each ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM35950(4-pyridinoxy-2-anilinopyridine-based compound, 14)
Affinity DataIC50:  30nM EC50:  35nMpH: 7.4 T: 2°CAssay Description:A fluorescence polarization assay was used to assess the ALK5 binding capacity and biochemical activity of compounds. ALK5 protein was added to each ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM35951(4-pyridinoxy-2-anilinopyridine-based compound, 15)
Affinity DataIC50:  109nM EC50:  146nMpH: 7.4 T: 2°CAssay Description:A fluorescence polarization assay was used to assess the ALK5 binding capacity and biochemical activity of compounds. ALK5 protein was added to each ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM35952(4-pyridinoxy-2-anilinopyridine-based compound, 16)
Affinity DataIC50:  21nM EC50:  27nMpH: 7.4 T: 2°CAssay Description:A fluorescence polarization assay was used to assess the ALK5 binding capacity and biochemical activity of compounds. ALK5 protein was added to each ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM35953(4-pyridinoxy-2-anilinopyridine-based compound, 17)
Affinity DataIC50:  12nM EC50:  31nMpH: 7.4 T: 2°CAssay Description:A fluorescence polarization assay was used to assess the ALK5 binding capacity and biochemical activity of compounds. ALK5 protein was added to each ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM35954(4-pyridinoxy-2-anilinopyridine-based compound, 18)
Affinity DataIC50:  129nM EC50:  63nMpH: 7.4 T: 2°CAssay Description:A fluorescence polarization assay was used to assess the ALK5 binding capacity and biochemical activity of compounds. ALK5 protein was added to each ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM35955(4-pyridinoxy-2-anilinopyridine-based compound, 19)
Affinity DataIC50:  72nM EC50:  22nMpH: 7.4 T: 2°CAssay Description:A fluorescence polarization assay was used to assess the ALK5 binding capacity and biochemical activity of compounds. ALK5 protein was added to each ...More data for this Ligand-Target Pair
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM282792(6-(1-(2,2-difluoroethyl)-4-(4-fluorophenyl)-1H- im...)
Affinity DataIC50:  1.60nMpH: 7.4 T: 2°CAssay Description:Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM282793(6-(4-(4-fluorophenyl)-1-cis-3-hydroxycyclobutyl)-1...)
Affinity DataIC50:  2.30nMpH: 7.4 T: 2°CAssay Description:Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM282794(6-(1-(3,3-difluorocyclobutyl)-4-(4-fluorophenyl)-1...)
Affinity DataIC50:  14.2nMpH: 7.4 T: 2°CAssay Description:Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM282795(6-(4-(4-fluorophenyl)-1-(3,3,3-trifluoropropyl)-1H...)
Affinity DataIC50:  6.80nMpH: 7.4 T: 2°CAssay Description:Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM282796(6-(1-(3,3-difluorocyclopentyl)-4-(4-fluorophenyl)-...)
Affinity DataIC50:  5.5nMpH: 7.4 T: 2°CAssay Description:Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM282797((S)-6-(4-(4-fluroophenyl)-1-(1-hydroxybutan-2-yl)-...)
Affinity DataIC50:  5nMpH: 7.4 T: 2°CAssay Description:Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM282798(6-(1-cyclopropyl-4-(4-fluorophenyl)-1H-imidazol-5-...)
Affinity DataIC50:  2.40nMpH: 7.4 T: 2°CAssay Description:Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM282799(6-(1-(4,4-difluorocyclohexyl)-4-(4-fluorophenyl)-1...)
Affinity DataIC50:  17.9nMpH: 7.4 T: 2°CAssay Description:Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM282800(6-(1-(2-fluoroethyl)-4-(4-fluorophenyl)-1H-imidazo...)
Affinity DataIC50:  1.90nMpH: 7.4 T: 2°CAssay Description:Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM282801(6-(1-ethyl-4-(4-fluorophenyl)-1H-imidazol-5- yl)im...)
Affinity DataIC50:  2.5nMpH: 7.4 T: 2°CAssay Description:Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM282802(6-(4-(4-fluorophenyl)-1-(2-isopropoxyethyl)-1H- im...)
Affinity DataIC50:  3nMpH: 7.4 T: 2°CAssay Description:Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM282803(6-(4-(4-fluorophenyl)-1-(3-hydroxy-3-methylbutyl)-...)
Affinity DataIC50:  2.10nMpH: 7.4 T: 2°CAssay Description:Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM282804(6-(4-(4-fluorophenyl)-1-(oxetan-3-yl)-1H-imidazol-...)
Affinity DataIC50:  17nMpH: 7.4 T: 2°CAssay Description:Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM282805(6-(4-(4-fluorophenyl)-1-(2-hydroxyethyl)-1H-imidaz...)
Affinity DataIC50:  5.30nMpH: 7.4 T: 2°CAssay Description:Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM282806(6-(4-(4-fluorophenyl)-1-(3-hydroxypropyl)-1H- imid...)
Affinity DataIC50:  2nMpH: 7.4 T: 2°CAssay Description:Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM282807(6-(1-(1-cyclopropyl-2-methoxyethyl)-4-(4- fluoroph...)
Affinity DataIC50:  2.30nMpH: 7.4 T: 2°CAssay Description:Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM282808(6-(4-(4-fluorophenyl)-1-(2-hydroxycyclohexyl)-1H- ...)
Affinity DataIC50:  3.5nMpH: 7.4 T: 2°CAssay Description:Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM282809(6-(4-(4-fluorophenyl)-1H-imidazol-5-yl)imidazo[1,2...)
Affinity DataIC50:  10.5nMpH: 7.4 T: 2°CAssay Description:Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM282810(6-(4-(4-fluorophenyl)-1-methyl-1H-imidazol-5- yl)i...)
Affinity DataIC50:  9.90nMpH: 7.4 T: 2°CAssay Description:Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM282811(6-(1-(3,3-difluoropropyl)-4-(4-fluorophenyl)-1H- i...)
Affinity DataIC50:  2.20nMpH: 7.4 T: 2°CAssay Description:Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM282812(6-(4-(4-fluorophenyl)-1-(3-fluoropropyl)-1H-imidaz...)
Affinity DataIC50:  1.90nMpH: 7.4 T: 2°CAssay Description:Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM282815(6-(1-(2,2-difluoropropyl)-4-(4-fluorophenyl)-1H- i...)
Affinity DataIC50:  1.20nMpH: 7.4 T: 2°CAssay Description:Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM282816(6-(1-(2-fluoro-2-methylpropyl)-4-(4-fluorophenyl)-...)
Affinity DataIC50:  1.90nMpH: 7.4 T: 2°CAssay Description:Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM282817(6-(4-(4-fluorophenyl)-1-isopropyl-1H-imidazol-5- y...)
Affinity DataIC50:  0.400nMpH: 7.4 T: 2°CAssay Description:Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM282818(6-(1-(bicyclo[1.1.1]pentan-1-yl)-4-(4-fluorophenyl...)
Affinity DataIC50:  2.60nMpH: 7.4 T: 2°CAssay Description:Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM282819(6-(4-(4-fluorophenyl)-1-(2-hydroxy-2-methylpropyl)...)
Affinity DataIC50:  92.6nMpH: 7.4 T: 2°CAssay Description:Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM282820(6-(4-(4-fluorophenyl)-1-(3- (hydroxymethyl)cyclobu...)
Affinity DataIC50:  0.600nMpH: 7.4 T: 2°CAssay Description:Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM282821((R)-6-(4-(4-fluorophenyl)-1-(4,4,4-trifluoro-1- hy...)
Affinity DataIC50:  1nMpH: 7.4 T: 2°CAssay Description:Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM282822((S)-6-(4-(4-fluorophenyl)-1-(4,4,4-trifluoro-1- hy...)
Affinity DataIC50:  6.40nMpH: 7.4 T: 2°CAssay Description:Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM282823(6-(4-(4-fluorophenyl)-1-(tert-pentyl)-1H-imidazol-...)
Affinity DataIC50:  9.20nMpH: 7.4 T: 2°CAssay Description:Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM282824(6-(4-(4-fluorophenyl)-1-((tetrahydrofuran-2-yl)met...)
Affinity DataIC50:  1.90nMpH: 7.4 T: 2°CAssay Description:Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM282825(6-(4-(3-chloro-4-fluorophenyl)-1-(2-hydroxyethyl)-...)
Affinity DataIC50:  1.80nMpH: 7.4 T: 2°CAssay Description:Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...More data for this Ligand-Target Pair
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM282826(6-(4-(3-chloro-4-fluorophenyl)-1-(2,2-difluoroethy...)
Affinity DataIC50:  1nMpH: 7.4 T: 2°CAssay Description:Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Astrazeneca

LigandPNGBDBM282827(6-(4-(3-chloro-4-fluorophenyl)-1-(2-fluoroethyl)-1...)
Affinity DataIC50:  0.900nMpH: 7.4 T: 2°CAssay Description:Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 363 total ) | Next | Last >>
Jump to: